{"id":"NCT00636168","sponsor":"Bristol-Myers Squibb","briefTitle":"Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma","officialTitle":"Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-06-30","primaryCompletion":"2013-07-26","completion":"2018-11-26","firstPosted":"2008-03-14","resultsPosted":"2014-08-19","lastUpdate":"2019-12-17"},"enrollment":1211,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["High Risk Stage III Melanoma"],"interventions":[{"type":"DRUG","name":"ipilimumab","otherNames":["BMS-734016","MDX-010"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"A","type":"ACTIVE_COMPARATOR"},{"label":"B","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to determine if ipilimumab is effective in preventing or delaying recurrence and prolongs survival after complete resection of high risk stage III melanoma","primaryOutcome":{"measure":"Recurrence Free Survival (RFS) Per Independent Review Committee (IRC) in the Intent to Treat (ITT) Population","timeFrame":"Date of randomization to first date of recurrence or death or last available disease assessment with RFS data up to 5 years. Median follow-up was 2.7 years.","effectByArm":[{"arm":"Ipilimumab 10mg/kg","deltaMin":26.09,"sd":null},{"arm":"Placebo","deltaMin":17.05,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0013"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":2},"locations":{"siteCount":97,"countries":["United States","Australia","Austria","Belgium","Canada","Czechia","Denmark","Finland","France","Germany","Italy","Netherlands","Norway","Poland","Russia","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["39378385","34663559","28162999","27717298","25840693"],"seeAlso":["http://bms.com/studyconnect/Pages/home.aspx","http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx","http://www.bms.com/studyconnect/Pages/home.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":257,"n":471},"commonTop":["Diarrhoea","Fatigue","Pruritus","Rash","Headache"]}}